Englumafusp alfa

恩璐玛芙普 α

Report date: 2025/02/01 20:00:06

Base Information

Drug NameEnglumafusp alfa
Drug Alias NameEnsomafusp alfaRG-6076RO-7227166
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitorsTumor necrosis factor receptor superfamily member 9 agonists
TargetsB-lymphocyte antigen CD19Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche AgF. Hoffmann-La Roche LtdRoche (China) Holding Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A